Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks quality of life in men on prostate cancer drug lutathera

NCT ID NCT06517719

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study follows 500 men with metastatic castration-resistant prostate cancer who are receiving lutetium-177 vipivotide tetraxetan (a radioactive drug) as part of their routine care. Researchers will measure quality of life, pain, and disease progression over time using patient questionnaires and medical records. The goal is to understand how this treatment works in real-world settings, outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lutetium-177 vipivotide tetraxetan (a radioactive drug that targets prostate cancer cells)
What this could lead to
If successful, this study will provide real-world data on how this treatment affects quality of life and disease progression in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult male patients with mCRPC

Ages

18 to 99 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients must meet the following inclusion criteria during the identification period: * Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1. * ≥ 18 years old at the time of enrollment * Written informed consent must be obtained prior to any data collection * Willing to participate in Quality of Life post treatment date collection for 1 year Exclusion Criteria: Patients must not meet the following exclusion criterion during the identification period: \- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic castration resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic castration resistant prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    38 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Konstanz, Baden-Wurttemberg, 78464, Germany

  • Novartis Investigative Site

    RECRUITING

    Stuttgart, Baden-Wurttemberg, 70174, Germany

  • Novartis Investigative Site

    RECRUITING

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    RECRUITING

    Regensburg, Bavaria, 93053, Germany

  • Novartis Investigative Site

    RECRUITING

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    RECRUITING

    Cottbus, Brandenburg, 03048, Germany

  • Novartis Investigative Site

    RECRUITING

    Frankfurt (Oder), Brandenburg, 15236, Germany

  • Novartis Investigative Site

    RECRUITING

    Ludwigshafen, Germany, 67063, Germany

  • Novartis Investigative Site

    RECRUITING

    Marburg, Hesse, 35043, Germany

  • Novartis Investigative Site

    RECRUITING

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    RECRUITING

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    RECRUITING

    Leipzig, Saxony, 04103, Germany

  • Novartis Investigative Site

    RECRUITING

    Halle, Saxony-Anhalt, 06120, Germany

  • Novartis Investigative Site

    RECRUITING

    Jena, Thuringia, 07740, Germany

  • Novartis Investigative Site

    RECRUITING

    Aachen, 52074, Germany

  • Novartis Investigative Site

    RECRUITING

    Augsburg, 86179, Germany

  • Novartis Investigative Site

    RECRUITING

    Berlin, 10249, Germany

  • Novartis Investigative Site

    RECRUITING

    Berlin, 12559, Germany

  • Novartis Investigative Site

    RECRUITING

    Berlin, 13125, Germany

  • Novartis Investigative Site

    RECRUITING

    Bielefeld, 33611, Germany

  • Novartis Investigative Site

    RECRUITING

    Bonn, 53105, Germany

  • Novartis Investigative Site

    RECRUITING

    Braunschweig, 38114, Germany

  • Novartis Investigative Site

    RECRUITING

    Chemnitz, 09113, Germany

  • Novartis Investigative Site

    RECRUITING

    Dortmund, 44137, Germany

  • Novartis Investigative Site

    RECRUITING

    Dortmund, 44309, Germany

  • Novartis Investigative Site

    RECRUITING

    Erfurt, 99089, Germany

  • Novartis Investigative Site

    RECRUITING

    Erlangen, 91054, Germany

  • Novartis Investigative Site

    RECRUITING

    Essen, 45147, Germany

  • Novartis Investigative Site

    RECRUITING

    Fulda, 36043, Germany

  • Novartis Investigative Site

    RECRUITING

    Herford, 32049, Germany

  • Novartis Investigative Site

    RECRUITING

    Homburg, 66421, Germany

  • Novartis Investigative Site

    RECRUITING

    Magdeburg, 39120, Germany

  • Novartis Investigative Site

    RECRUITING

    Mainz, 55131, Germany

  • Novartis Investigative Site

    RECRUITING

    Nuremberg, 90419, Germany

  • Novartis Investigative Site

    RECRUITING

    Rostock, 18057, Germany

  • Novartis Investigative Site

    RECRUITING

    Trier, 54290, Germany

  • Novartis Investigative Site

    RECRUITING

    Tübingen, 72076, Germany

  • Novartis Investigative Site

    RECRUITING

    Ulm, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.